Physician profile
Laertes A Manuelidis
NPI 1245220698
$252,394.56
in general payments reported to CMS, 2019-2025
11 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.49 · 2020: $13K · 2021: $70K · 2022: $27K · 2023: $42K · 2024: $40K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Consulting Fee: $34K · Travel and Lodging: $8,772 · Food and Beverage: $4,199 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,374.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $46,565.00 |
| Consulting Fee | $33,789.00 |
| Travel and Lodging | $8,771.56 |
| Food and Beverage | $4,199.22 |
| Education | $254.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $249,741.85 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $1,422.45 | 2021-2023 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $459.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $403.25 | 2022-2025 | |
| Biofrontera INC. | $122.21 | 2025 | |
| Lilly USA, LLC | $103.06 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $73.44 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $20.90 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $16.75 | 2023 | |
| Genzyme Corporation | $15.75 | 2025 | |
| Incyte Corporation | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laertes Manuelidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.